MM
Maria-Luisa Maccecchini (President & CEO) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales, 1 filed past the two-business-day deadline), most often in Annovis Bio, Inc. (ANVS). Across 1 priced purchase filing, the average 21-session return was +127.4% from execution and +74.7% from disclosure (delay-adjusted; derived). The median gap between execution and disclosure was 15 days. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+127.4%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+74.7%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells · 1 late
Median delay
15d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
–
no filings in the window
Last traded
Oct 28 2025
Filed Nov 12 2025
Median ADV $1.2M across their filed names
Open performance→Volume by month
Buys $200K
Sells $0
Shares × price, as filed · by filing month · past 24 months
Most traded names
ANVSRecent filings
ANVSPURCHASE
Annovis Bio, Inc.
View filing →
$200K97,561 sh × $2.05
Exec Oct 28 2025
Filed Nov 12 2025 · 9:19 AM ET †